Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
Finding the right balance between price and quality can challenge even the most skilled investors. Luckily for you, we started StockStory to help you identify the real opportunities. Keeping that in mind, here are three high-flying stocks facing an uphill battle and some alternatives you should consider instead.
Amkor (AMKR)
Forward P/E Ratio: 30.4x
Operating through a largely Asian facility footprint, Amkor Technologies (NASDAQ: AMKR) provides outsourced packaging and testing for semiconductors.
Why Are We Out on AMKR?
- Products and services resonate with customers, evidenced by its respectable 6.2% annualized sales growth over the last five years
- Gross margin of 14.3% is below its competitors, leaving less money to invest in areas like marketing and R&D
- Investment activity picked up over the last five years, pressuring its weak free cash flow margin of 2.9%
Amkor is trading at $71.15 per share, or 30.4x forward P/E. Check out our free in-depth research report to learn more about why AMKR doesn’t pass our bar.
Inspire Medical Systems (INSP)
Forward P/E Ratio: 54.6x
Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE: INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep.
Why Are We Wary of INSP?
- Modest revenue base of $915.2 million gives it less fixed cost leverage and fewer distribution channels than larger companies
- Estimated sales decline of 8% for the next 12 months implies a challenging demand environment
At $49.67 per share, Inspire Medical Systems trades at 54.6x forward P/E. If you’re considering INSP for your portfolio, see our FREE research report to learn more.
Warby Parker (WRBY)
Forward P/E Ratio: 54.1x
Founded in 2010, Warby Parker (NYSE: WRBY) designs, manufactures, and sells eyewear, including prescription glasses, sunglasses, and contact lenses, through its e-commerce platform and physical retail locations.
Why Does WRBY Worry Us?
- Subscale operations are evident in its revenue base of $890.6 million, meaning it has fewer distribution channels than its larger rivals
- Suboptimal cost structure is highlighted by its history of operating margin losses
- Push for growth has led to negative returns on capital, signaling value destruction
Warby Parker’s stock price of $28.71 implies a valuation ratio of 54.1x forward P/E. Read our free research report to see why you should think twice about including WRBY in your portfolio.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
